New daily pill aims to stop HAE attacks, but trial cut short

NCT ID NCT05055258

Terminated Disease control Sponsor: KalVista Pharmaceuticals, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested KVD824, an oral pill, to prevent swelling attacks in people with hereditary angioedema types I and II. The study planned to compare three doses against a placebo over several months. However, the trial was terminated early with only 33 participants, so the results are not reliable enough to draw firm conclusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

KVD824 (an oral plasma kallikrein inhibitor)

What this could lead to

If it works, this could provide a convenient daily pill to prevent painful swelling attacks in people with hereditary angioedema.

What could go wrong

The trial was stopped early with only 33 participants, so we don't have enough data to know if it works or is safe. It may not be effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary angioedema type 1 hereditary angioedema type 2 Hereditary Angioedema Types I and II hereditary angioedema with C1Inh deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANGIOEDEMA, HEREDITARY, TYPES I AND II

Contacts and locations

Show contact details

Locations

KalVista Investigative Site

Birmingham, Alabama, 35294, United States
KalVista Investigative Site

Scottsdale, Arizona, 85251, United States
KalVista Investigative Site

La Jolla, California, 92093, United States
KalVista Investigative Site

Santa Monica, California, 90404, United States
KalVista Investigative Site

Centennial, Colorado, 80112, United States
KalVista Investigative Site

Tampa, Florida, 33620, United States
KalVista Investigative Site

Chevy Chase, Maryland, 20815, United States
KalVista Investigative Site

Boston, Massachusetts, 02114, United States
KalVista Investigative Site

St Louis, Missouri, 63110, United States
KalVista Investigative Site

Cincinnati, Ohio, 45231, United States
KalVista Investigative Site

Hershey, Pennsylvania, 17033, United States
KalVista Investigative Site

Dallas, Texas, 75390, United States
KalVista Investigative Site

Spokane, Washington, 99204, United States
KalVista Investigative Site

Campbelltown, New South Wales, Australia
KalVista Investigative Site

Sofia, Bulgaria
KalVista Investigative Site

North York, Ontario, Canada
KalVista Investigative Site

Brno, Czechia
KalVista Investigative Site

Prague, Czechia
KalVista Investigative Site

Grenoble, France
KalVista Investigative Site

Paris, France
KalVista Investigative Site

Mainz, Rhineland-Palatinate, Germany
KalVista Investigative Site

Berlin, Germany
KalVista Investigative Site

Frankfurt am Main, Germany
KalVista Investigative Site

Budapest, Hungary
KalVista Investigative Site

Milan, Italy
KalVista Investigative Site

Padova, Italy
KalVista Investigative Site

Grafton, Auckland, New Zealand
KalVista Investigative Site

Skopje, North Macedonia
KalVista Investigative Site

San Juan, Puerto Rico
KalVista Investigative Site

Birmingham, United Kingdom
KalVista Investigative Site

Leeds, United Kingdom
KalVista Investigative Site

London, United Kingdom
KalVista Investigative Site

Newcastle upon Tyne, United Kingdom